Study predicting the response to induction chemotherapy of three courses of Docetaxel, Cisplatin and 5-Fluorouracil, inoperable squamous cell carcinoma of the upper aero-digestive tract stages T3 or T4, any N, MO, by micro analysis chip-transcriptional changes induced by the first tumor cure. [Etude de prédiction de la réponse à une chimiothérapie d'induction de 3 cures de Docetaxel, Cisplatine et 5-Fluorouracile, des carcinomes épidermoïdes des voies aéro-digestives supérieures de stades T3 ou T4, tout N, MO, inopérables, par analyse en micro-puces des modifications transcriptionnelles tumorales induites par la première cure]

Trial Profile

Study predicting the response to induction chemotherapy of three courses of Docetaxel, Cisplatin and 5-Fluorouracil, inoperable squamous cell carcinoma of the upper aero-digestive tract stages T3 or T4, any N, MO, by micro analysis chip-transcriptional changes induced by the first tumor cure. [Etude de prédiction de la réponse à une chimiothérapie d'induction de 3 cures de Docetaxel, Cisplatine et 5-Fluorouracile, des carcinomes épidermoïdes des voies aéro-digestives supérieures de stades T3 ou T4, tout N, MO, inopérables, par analyse en micro-puces des modifications transcriptionnelles tumorales induites par la première cure]

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Jul 2012

At a glance

  • Drugs Cisplatin (Primary) ; Docetaxel (Primary) ; Fluorouracil (Primary)
  • Indications Head and neck cancer
  • Focus Pharmacodynamics; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 03 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top